Barrington analyst Michael Petusky lowered the firm’s price target on Dentsply Sirona (XRAY) to $18 from $21 and keeps an Outperform rating on the shares. The firm updated the company’s model post the in-line Q2 report. It sees a favorable risk/reward at current valuation levels with its price target representing 36% upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona price target lowered to $24 from $25 at UBS
- DENTSPLY SIRONA: Hold Rating Amid Strong Earnings, Leadership Changes, and Market Challenges
- DENTSPLY SIRONA: Hold Rating Amidst Sales Pressure and Strategic Leadership Transition
- Dentsply Sirona Reports Q2 2025 Financial Results
- DENTSPLY SIRONA: Hold Rating Maintained Amidst Mixed Performance and Promising Margin Improvements